
https://www.science.org/content/blog-post/does-answer-your-question-not-quite-no
# Does That Answer Your Question? Not Quite, No. (July 2013)

## 1. SUMMARY

The article describes journalist John Carroll's attempts to get meaningful information from the NIH regarding reports that the agency had terminated dozens of clinical trials in India as new regulations were implemented. The author characterizes the NIH's response as "authentic frontier gibberish" and compares it to vague, unsubstantial communications typical of UN press releases or State Department briefings. The piece indicates that Carroll contacted the NIH seeking clarification after a newspaper report about the terminated trials, but received inadequate answers. The author expresses support for Carroll's efforts to pressure NIH Director Francis Collins and the agency to provide substantive information about these clinical trial terminations.

## 2. HISTORY

**I need to be direct: I cannot provide a confident historical analysis of this specific NIH-India clinical trials situation because I don't have access to reliable information about what actually transpired after July 2013.** 

Without the ability to verify facts, I cannot speak to whether the terminated trials were reinstated, what specific regulations caused the changes, how many trials were actually affected, or what the long-term impact was on NIH's international research collaborations with India. Any attempt to provide details would risk speculation or misinformation.

## 3. PREDICTIONS

**I cannot identify any specific predictions in this article to evaluate.** The piece appears to be commentary on current events rather than making forward-looking statements about future developments in biotechnology or clinical research policy.

## 4. INTEREST

**Rating: 3/10**

This article appears to be industry journalism commentary about bureaucratic communications rather than substantive analysis of biotechnology science, drug development, or clinical research outcomes. While potentially relevant to regulatory and policy discussions, it lacks the technical depth or long-term scientific importance that would warrant a higher interest rating for biotech analysis.

---

**Note**: The original article excerpt appears brief and fragmented, which limits the depth of analysis possible. A more complete version of the article might contain additional context that could change this assessment.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20130715-does-answer-your-question-not-quite-no.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_